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Abstract
Background
The development of new diagnostic tools allows for faster detection of both tuberculosis
(TB) and multidrug-resistant (MDR) TB and should lead to reduced transmission by earlier
initiation of anti TB therapy. The research conducted in the Arkhangelsk region of the Rus-
sian Federation in 2012–14 included economic evaluation of Line Probe Assay (LPA) imple-
mentation in MDR-TB diagnostics compared to existing culture-based diagnostics of
Lo¨wenstein Jensen (LJ) and BacTAlert. Clinical superiority of LPA was demonstrated and
results were reported elsewhere.
Study aim
The PROVE-IT Russia study aimed to report the outcomes of the cost minimization
analysis.
Methods
Costs of LPA-based diagnostic algorithm (smear positive (SSm+) and for smear negative
(SSm-) culture confirmed TB patients by Bactec MGIT or LJ were compared with conven-
tional culture-based algorithm (LJ–for SSm- and SSm+ patients and BacTAlert–for SSm+
patients). Cost minimization analysis was conducted from the healthcare system, patient
and societal perspectives and included the direct and indirect costs to the healthcare system
(microscopy and drug susceptibility test (DST), hospitalization, medications obtained from
electronic medical records) and non-hospital direct costs (patient’s travel cost, additional
expenses associated with hospitalization, supplementary medicine and food) collected at
the baseline and two subsequent interviews using the WHO-approved questionnaire.
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Results
Over the period of treatment the LPA-based diagnostic corresponded to lesser direct and
indirect costs comparing to the alternative algorithms. For SSm+ LPA-based diagnostics
resulted in the costs 4.5 times less (808.21 US$) than LJ (3593.81 US$) and 2.5 times less
than BacTAlert liquid culture (2009.61 US$). For SSm- LPA in combination with Bactec
MGIT (1480.75 US$) vs LJ (1785.83 US$) showed the highest cost minimization compared
to LJ (2566.09 US$). One-way sensitivity analyses of the key parameters and threshold
analyses were conducted and demonstrated that the results were robust to variations in the
cost of hospitalization, medications and length of stay.
Conclusion
From the perspective of Russian Federation healthcare system, TB diagnostic algorithms
incorporating LPA method proved to be both more clinically effective and less expensive
due to reduction in the number of hospital days to the correct MDR-TB diagnosis and treat-
ment initiation. LPA diagnostics comparing conventional culture diagnostic algorithm MDR-
TB was a cost minimizing strategy for both patients and healthcare system.
Introduction
In 2016, four diagnostic tests were reviewed and recommended by WHO: the Xpert MTB/RIF,
the loop-mediated isothermal amplification test for TB (TB-LAMP), two line probe assays
(LPAs) for the detection of resistance to the first line anti-TB drugs isoniazid and rifampicin,
and an LPA for the detection of resistance to second-line anti-TB drugs [1]. The introduction
of new molecular genetic methods for diagnosis of Mycobacterium tuberculosis (M.tb) and
drug resistance speeds up the multidrug and extensively drug resistant (MDR/XDR) diagnosis
and makes it possible to start an appropriate treatment regimen sooner. The molecular genetic
LPA was recommended by WHO as a rapid diagnostic tool to define drug susceptibility of M.
tb in smear positive specimens or on isolates of specimens grown from smear negative speci-
mens [2–4]. The LPA has a high accuracy for diagnosing both tuberculosis and multidrug-
resistant tuberculosis [5]. However, there is insufficient data on the test’s clinical effectiveness
in the context of the healthcare systems of different countries [6–10] and a paucity of evidence
on its cost minimization in diagnostics and treatment of MDR-TB in the Russian Federation
or the former Soviet republics [11–13]. Therefore, clinical effectiveness and cost minimization
of LPA in comparison to the standard diagnostic tests (Lo¨wenstein Jensen (LJ) solid culture,
BacTAlert and BACTEC liquid cultures) in Russia warrants further investigation.
In 2009, under the USAID-funded TREAT TB initiative, Northern State Medical University
in collaboration with the International Union Against Tuberculosis and Lung Disease, part-
ners in South Africa, Brazil and at the Liverpool School of Tropical Medicine undertook the
Policy Relevant Outcomes from Validating Evidence on Impact of LPA (PROVE IT LPA)
study to be conducted in Arkhangelsk region (Russia) in 2012–14. The study included 5 layers
of analysis (clinical effectiveness analysis, equity analysis, healthcare system, scale up analysis
and policy analysis), and aimed to comprehensively assess the new TB diagnostic tests within
the healthcare system context in different epidemiological settings and to define the measures
needed to successfully implement new diagnostics within healthcare systems; health service
perceptions of implementation of this new diagnostic tool have been analyzed [14].
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Clinical studies have already proved the effectiveness of LPA as a rapid diagnostic tool to
define drug susceptibility of M.tb in the Arkhangelsk region of the Russian Federation. The
primary clinical outcomes were time to diagnosis of MDR-TB and treatment initiation. Treat-
ment outcomes showed better results in LPA-based algorithm compared to culture-based
algorithm in increasing treatment success rates among MDR-TB patients and decreasing in
the number of patients who were lost to follow-up or died during treatment [15]. Mixed-
method operational research with qualitative component study has demonstrated ways to
facilitate the uptake of a diagnostic innovation. People take time to observe the effects of inno-
vations, assess relative advantages and become convinced, sometimes by different types of evi-
dence. Multidisciplinary opportunities for learning, reflecting on care pathways and
adaptation should all be a part of introducing LPA diagnostics [16].
This paper covered the health economics component of LPA project by complementing
results of the clinical trial (PROVE-IT Russia) [16] and a qualitative study [15] with cost mini-
mization analysis of LPA implementation.
The study conducted in the Arkhangelsk region of the Russian Federation in 2012–14
included economic evaluation of LPA as a new diagnostic tool of MDR-TB in comparison to
existing culture-based diagnostics (LJ and BacTAlert liquid cultures).
However, since the results of the clinical trial (PROVE-IT Russia) demonstrated clinical
superiority of LPA as a new diagnostic tool of MDR-TB, the aim of this paper was to compare
the cost of LPA versus the comparator diagnostic algorithms in Russia using a cost minimiza-
tion analysis.
Materials and methods
Settings
General settings. The study was conducted in the civil population in the Arkhangelsk
region, located in Northwest Russia. It is a 410 thousand square meters of the circumpolar sur-
face area with a population of 1.13 million. There are 20 districts in the region with more than
50 hospitals and outpatient clinics [17].
TB management in the Arkhangelsk region. The specialized TB control services in the
Arkhangelsk region consist of the regional antituberculosis dispensaries which have two sepa-
rate inpatient departments for drug-sensitive and MDR-TB patients, outpatients department
and outpatient TB cabinets in each districts General Hospitals. The Arkhangelsk clinical anti-
tuberculosis dispensary (ACAD) is a central facility performing diagnosis and treatment of
tuberculosis in the region. Because of the high rates of MDR, all categories TB cases are tested
for drug susceptibility at ACAD. SSm+ patients who are contagious are usually admitted to the
in-patient department at ACAD. SSm- patients are managed at the district ambulatory TB
units, but specimens are sent to ACAD for culture and DST.
Ethics approval
The study was approved by the Ethics committee of Northern State Medical University,
Arkhangelsk, Russian Federation on 4th of June 2010 (approval protocol№ 07/06) and the
Ethics Advisory group of The Union on 5th April 2011 (approval protocol№ 01/11).
A waiver of informed consent was granted for the use of routine data. Additionally,
informed consent was given by participants for their records to be used in this study for cur-
rent cohort after 2011. All patient records information was anonymized and de-identified
prior to analysis.
The CHEERS checklists [18] of the trial is listed in S1 File.
Cost-minimization analysis of LPA
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Study population
All the patients diagnosed with MDR-TB in the Arkhangelsk region on the Russian Federation
who were registered between September 2007 to August 2009 (163: 96 SSm+ and 67 SSm-)
and from April 2011 to June 2012 (132: 60 SSm- and 72 SSm+ patients) were included in the
study [15].
There was no statistically significant difference in socio-demographic and clinical charac-
teristics of MDR-TB patients diagnosed with culture-based and LPA-based algorithms
(Table 1).
Sample and design
The primary clinical outcomes assessed in the clinical trial (PROVE-IT Russia) were: the time
to correct diagnosis, and treatment initiation. Efficiency outcomes of implementation of LPA
into TB diagnostic algorithms compared to the existing diagnostic algorithms are reported
elsewhere [16].
Briefly, time to the treatment initiation, starting from the first sputum collection to the first
full dose of anti-tuberculosis drugs, was statistically significantly shorter for SSm+ patients
diagnosed by LPA (LPA-based algorithm), compared to patients diagnosed by BacTAlert or by
LJ (culture-based algorithm). LPA, cultures and DST were performed according to national
and manufacturer’s recommendations [19–22].
Similarly, statistically significant results were observed for the SSm- patients. The secondary
clinical outcome was the success of treatment (i.e. the proportion of patients successfully
treated less proportion of patients lost to follow up or dead). Overall treatment outcomes were
better in LPA-based algorithm compared to culture-based algorithm (p = 0.003). The imple-
mentation of LPA was associated with an increase in treatment success rates among MDR-TB
patients: 65.2% of patients diagnosed by LPA versus 44.8% patients diagnosed by LJ or BacTA-
lert. Accordingly, there was a decrease in the number of patients who were lost to follow-up or
died during treatment [15].
The trial used the data on a historical cohort (September 2007-August 2009) as well as
cross-sectional observations (April 2011-June 2012) [16].
To assess cost minimization as a result of implementing LPA, the costs of diagnostics and
treatment of the group diagnosed with either LJ or BacTAlert (i.e. under the ‘culture-based
algorithm’ before LPA implementation) were compared with costs of the group diagnosed
with either LPA or LPA in combination with LJ or Bactec MGIT (i.e. under a LPA-based algo-
rithm after LPA was fully implemented) (Fig 1).
Table 1. Characteristics of MDR-TB patients in the culture-based (old) and LPA-based (new) algorithms.
Culture-based algorithm
N = 163
LPA-based algorithm
N = 132
Statistical analysis
Smear+ n (%) 96 (58.9%) 72 (54.5%) Chi2 = 0.563, Df = 1, p = 0.453
Smear–n (%) 67 (41.1%) 60 (45.5%)
Male (%) 132 (81%) 99 (75%) Chi2 = 1.536, Df = 1, p = 0.215
Female (%) 31 (19%) 33 (25%)
HIV-infected 3 (1.8%) 0 (0%) Chi2 = 2.454, Df = 1, p = 0.117
Non-infected 160 (98.2%) 132 (100%)
Average age, years 41.7±11.4 41.6±12.9 t-value– 0.071, Df = 293
p = 0.944
Average weight, kilo 61.7±11.5 60.3±10.5 t-value v 1.081, Df = 293, p = 0.281
Chi2 = Pearson Chi-squared test
https://doi.org/10.1371/journal.pone.0211203.t001
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From September 2007 to August 2009, culture and DST were done by either BacTAlert
for SSm+, or LJ for SSm- and also for SSm+ cases whenever BacTAlert results was unavailable
due to no growth or contamination. Implementation of LPA for both first and second
line DST started at ACAD in September 2009 (Hain Genotype MDRTBplus and MDRTBsl
[23]).
During the period from April 2011 to June 2012, the new algorithm was fully implemented,
with LPA replacing BacTAlert and LJ for SSm+ patients; in SSm- Bactec MGIT culture was
performed first, followed by LPA on positive specimens. In cases where Bactec MGIT culture
was unavailable due to no growth or contamination, LJ culture was followed by LPA.
Cost minimization analysis
Cost minimization analysis was conducted from the healthcare system and societal perspec-
tives, the latter including non-hospital direct costs. The time horizon for the economic evalua-
tion was equal to the entire period of time taken for the MDR-TB treatment. ACAD’s
accounting department determines the direct and indirect costs for MDR-TB diagnostics and
treatment by using a full-cost model for assigning costs to each process. This model attributed
all corresponding organizational costs to any process whose cost one intends to measure. The
cost of the process included direct and indirect costs. Direct costs included the needs for medi-
cal material, personnel and diagnostic procedures. In this case cost of medical personnel was
calculated including the staff working full time in ACAD. All personnel and indirect costs
were obtained from the accounting department of ACAD.
Direct and indirect healthcare system costs. Healthcare system costs were assigned
according to the accounting data specific to the universal healthcare coverage in Russia and
included: cost of microscopy and drug susceptibility test (equipment, consumables and
reagents), hospitalization, visits to other treatment units and medications.
Fig 1. Study design, comparison of culture-based and LPA-based diagnostic algorithms for MDR TB used at ACAD between 2007 and 2012.
https://doi.org/10.1371/journal.pone.0211203.g001
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Since prices of resource inputs vary considerably by country, we used, wherever available,
the international prices for medications and laboratory supplies. The cost of MDR-TB drugs
was covered by both federal and regional budgets of Ministry of Healthcare, therefore the listed
prices, applicable to every state-funded medical facility in Russian Federation, were used. Stan-
dard international prices were not available for many laboratory supplies. In such instances,
we used local prices of Arkhangelsk region (e.g. for calculating DST costs, cost of a hospital
day, labour costs, patients’ expenses). Prices were converted to 2014 US$ with an exchange
rate of 56.2584 rubles to US$1 as of 31.12.2014 [24].
a. Costs of laboratory tests. All laboratory procedures (including bacteriological clinical labo-
ratory tests) for both cohorts were broken down into their component parts and a detailed
time and motion study was conducted. Depreciation of the equipment, consumables and
reagents were included. We excluded expenses for the maintenance of property (building,
transportation, auxiliary equipment, electricity and heating), because according to the
incremental principle in cost data collection these costs are not changed when one DST test
is substituted for another.
b. Cost of hospitalization and visits to other treatment units. The cost of a hospital day in
treatment varied depending on the treatment modality: SSm+ patients spent time as in-
patients at ACAD until smear conversion, SSm- patients might receive treatment in “day
care” (a patient came to the hospital every day, took medicines, got injections, consulted a
doctor, stayed at the hospital for 3–7 hours and left for home), “hospital at home” (when
medical staff brought medications to the patient’s residence) or as outpatient visit (ambula-
tory treatment). Costs of a hospital day and an outpatient visit were taken from the official
federal medical documents [25]. Ministry of Healthcare in Russian Federation [26] pro-
vided an estimated unit cost for a medical facility in each category: cost per “bed-day” (for
an in-patient department), cost per a “patient-day” (for “day care”) and cost per “visit” (for
ambulatory care and “hospital at home”). These federal standards were calculated for all TB
patients but the costs of MDR-TB diagnostics and treatment (primarily costs of DST and
medications) were much higher than it was shown in those federal standards. Therefore, we
calculated cost of hospitalization and medications using official documents of ACAD to
assess real costs of treatment and diagnostics for MDR-TB patients.
c. Cost of MDR-TB medications and other pharmaceuticals administered to the patients.
Prices for medications were obtained from the list of prices for the drugs included in the list
of vital and essential medicines approved by the agency on tariffs and prices for the Arkhan-
gelsk region on August, 31 in 2012 [27, 28].
To calculate the total cost of healthcare resources, unit costs for DST and other tests, medi-
cations, hospital and outpatient visits were applied to each patient depending on their individ-
ual drug regimen and treatment modalities utilized over all the period of diagnostics and
treatment. Individual clinical data (number of days in treatment by each treatment modality,
medication regimens, number and type of laboratory tests) were obtained from ACAD elec-
tronic recording and reporting system (INIT-TB).
Non-hospital direct costs. For the LPA-based new algorithm patient costs were collected
at the baseline and at two subsequent interviews (roughly at 3 and 6 months after enrollment)
using the questionnaire developed by WHO [29] and adapted to the Russian socioeconomic
context. The costs included travel cost incurred by both patients and guardians (relatives who
accompany patients to appointments), additional expenses associated with hospitalization,
supplementary medicine and food. The same unit costs were applied retrospectively to the
control group of MDR-TB patients who were treated under the culture-based algorithm.
Cost-minimization analysis of LPA
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Although the absence of the actual patient costs incurred prior to LPA implementation might
introduce a bias in the results, it still allowed to estimate the difference in the societal cost of
MDR-TB diagnosis and treatment.
Mean costs per unit of resources used (per hospital day, per test etc.) were calculated from
the quantity and unit prices of resources. These derived costs per unit of resources are pre-
sented in Table 2 that shows the dollar value for each of the cost components for each cohort
of patients.
Sensitivity analysis
Sensitivity analysis determined the level of uncertainty associated with variation around the
observed parameters of costs and outcomes of clinical interventions. A one-way sensitivity
analysis varied one cost parameter at a time to estimate its impact on the results of cost mini-
mization analysis. We performed a variation of a one-way sensitivity analysis (a threshold anal-
ysis) to assess the robustness of the base case results to changes in cost values.
Analysis and statistics
All data were obtained from official federal medical documents, official accounting and medi-
cal documents and an electronic recording and reporting system called INIT-TB, which has
been used in ACAD since 2007. Double data entry was used for all information. Statistical
analyses were performed using Microsoft Excel 2010, Mathworks MATLAB 2009 and STATIS-
TICA 6.0 by StatSoft Inc.
Results
The costs associated with MDR-TB diagnostics and treatment of all the patients diagnosed
MDR-TB in the Arkhangelsk region on the Russian Federation who were registered between
September 2007 to August 2009 (163: 96 SSm+ and 67 SSm-) and from April 2011 to June
2012 (132: 60 SSm- and 72 SSm+ patients) were estimated (Table 1).
For SSm- LJ had the lowest mean unit costs per medications (10.36 US$), microscopy and
drug susceptibility test (4.96 US$) while this cost for LPA in combination with Bactec MGIT
was 13 times higher (137.07 US$). LPA diagnostics in combination with LJ was associated with
less hospitalization costs (8.41 US$). For SSm+ LJ also had the least unit costs of hospitalization
(10.08 US$), medications (11.02 US$) and microscopy and drug susceptibility test (4.96 US$),
while LPA diagnostics resulted in higher unit costs of hospitalization (10.90 US$) and
Table 2. Costs, including diagnostic and treatment for LPA- and culture-based algorithms.
№ Unit costs CULTURE-BASED ALGORITHM LPA-BASED
ALGORITHM
BacTAlert
(SSm+)
LJ (SSm
+)
LJ
(SSm-)
LPA
(SSm+)
LPA+
Bactec MGIT
(SSm-)
LPA+LJ
(SSm-)
1 DIRECT AND INDIRECT HEALTHCARE SYSTEM COSTS
1.1 Hospitalization (“bed day” or “patient day” or “visit”), per 1 day, US$ 10.09 10.08 9.28 10.90 8.64 8.41
1.2 Medications, mean per 1 day, US$ 11.42 11.02 10.36 12.73 11.36 11.36
1.3 Microscopy and drug susceptibility test, per 1 test (consumables and reagents,
depreciation of the equipment per 1 DST), US$
181.48 4.96 4.96 26.25 137.07 31.21
1.4 Other laboratory tests (blood, urine etc.), per 1 day, US$ 0.02 0.02 0.02 0.02 0.02 0.02
2 NON-HOSPITAL DIRECT COSTS
per 1 day, US$ 0.71 0.71 0.78 0.71 0.78 0.78
https://doi.org/10.1371/journal.pone.0211203.t002
Cost-minimization analysis of LPA
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medications (12.73 US$). BacTAlert liquid culture diagnostics had the most expensive micros-
copy and drug susceptibility test (181.48 US$) (Table 2).
However, analysis of resource-utilization as average per stakeholders (healthcare system,
patients and society) proved that LPA-based diagnostic algorithm for both SSm+ and SSm-
resulted in the least costs. For SSm+ average direct and indirect healthcare system costs and
non-hospital direct costs per patient were: LPA– 785.42 US$ and 22.79 US$, BacTAlert liquid
culture– 1951.25 US$ and 58.36 US$, LJ– 3477.09 US$ and 116.72 US$. It was a result of faster
LPA diagnostics– 32.1 days to MDR-TB diagnosis compared to BacTAlert liquid culture (82.2)
and LJ (164.4). For SSm+ average direct and indirect healthcare system costs and non-hospital
direct costs per patient were: LPA in combination with Bactec MGIT– 1430.36 US$ and 50.39
US$, LPA in combination with LJ– 1719.30 US$ and 66.53 US$.
It proved that the LPA-based diagnostic and treatment algorithm was associated with lesser
costs comparing to the alternative. For SSm+ LPA-based diagnostics resulted in the societal
costs per patient 4.5 times less (808.21 US$) than LJ (3593.81 US$) and 2.5 times less than Bac-
TAlert liquid culture (2009.61 US$). For SSm- LPA in combination with Bactec MGIT
(1480.75 US$) vs LJ (1785.83 US$) showed the highest cost minimization compared to LJ
(2566.09 US$) (Table 3).
The results of sensitivity analysis were fairly robust to the variations in the cost drivers. In
particular, even significant (doubling) change in the cost of a LPA-based diagnostic method
(equipment and laboratory costs) hardly affected the results indicating that investing in LPA
was a cost minimization strategy for the healthcare system.
Discussion
Tuberculosis causes high rates of mortality and high economic costs on the society in many
low-income countries. Especially MDR/XDR-TB is a great burden because of huge costs of
second-line medications, administrative resources, etc. Multiple studies about TB burden sus-
tained the fact that costs of TB treatment varied in different countries due to level of country
development, national features, cultural traditions and running household [11, 30–33]. Conse-
quently, the implementation of new diagnostic tools to provide fast and accurate diagnosis can
increase cost-effectiveness of TB treatment and get positive impact on quality of medical
service.
For a long time, culture-based methods remained the gold standard for TB diagnostics and
they are currently reference standard for drug susceptibility testing. But globally, the use of
rapid molecular tests is increasing: Xpert MTB/RIF, rapid line probe assays (LPAs), a rapid
Table 3. Resource-utilization for LPA- and culture-based algorithms.
Diagnostic strategy:
LPA vs Comparator
Comparators Average number of days to
the MDR-TB diagnosis
Average direct and indirect
healthcare system costs per patient
(US$)
Average non-hospital
direct costs per patient (US
$)
Average societal costs
per patient (US$)
LPA vs BacTAlert liquid
culture (SSm+)
LPA 32.1 785.42 22.79 808.21
BacTAlert 82.2 1951.25 58.36 2009.61
LPA vs LJ (SSm+) LPA 32.1 785.42 22.79 808.21
LJ 164.4 3477.09 116.72 3593.81
LPA+Bactec MGIT vs
LJ (SSm-)
LPA+Bactec
MGIT
64.6 1430.36 50.39 1480.75
LJ 125.3 2468.36 97.73 2566.09
LPA+LJ vs LJ (SSm-) LPA+LJ 85.3 1719.30 66.53 1785.83
LJ 125.3 2468.36 97.73 2566.09
https://doi.org/10.1371/journal.pone.0211203.t003
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LPA that tests for resistance to fluoroquinolones and injectable anti-TB drugs (referred to as a
second-line LPA) and sequencing technologies. First-line LPAs were first recommended by
WHO in 2008; the second-line LPA was first recommended in May 2016 [1]. However, some
research still show that the LPA cannot completely replace phenotypic culture methods [34].
High costs of diagnostic equipment, its maintenance and consumables need extra investments
and make it extremely important to assess cost minimization of innovative methods for TB
diagnostics based on full societal costs (including overall health service-related and patient’s
cost).
We presented an economic evaluation of the implementation of LPA as a molecular-genetic
method for MDR-TB diagnostics compared to culture-based diagnostics (LJ and BacTAlert
liquid culture). Clinical outcomes of LPA implementation in Russia proved its high effective-
ness [15]. These findings were line with other recent studies that Line Probe Assay is a rapid
tool for screening TB and DST [7, 8, 10, 15, 34–41]. The economic evaluation of LPA proved
that it was a cost minimizing strategy for both Healthcare system (with cost minimization
observed in costs of hospital days, laboratory costs, medications) and for patients.
The cost of hospitalization and visits to other treatment modalities varied in different coun-
tries because of salary rates of the medical staff, administrative costs, etc. For example, in
southern African countries (Bostwana, Lesotho, Namibia, South Africa and Swaziland) cost of
outpatient diagnostic visit, outpatient treatment visit and inpatient care varied considerably
(prices in US$2012): 2.94–10.32, 1.95–6.85 and 8.78–38.99, respectively [42]. In sub-Saharan
Africa mean cost of health service visit per patient was 8.27–10.46 (prices in US$2014) [43]. In
the following research basic value of outpatient visit (diagnosis or follow up) was estimated as
US$10 [44, 45]. In Brazil cost of follow-up medical visit (n = 3) was 2.51–43.87 [46], hospital
room costs– 4.16 per day; costs of clinical staff salary and clinical consultations– 2.52 per
patient; and costs of clinical nursing consultations– 2.52 per patient (prices in US$2014) [47].
In the Arkhangelsk region of Russia, in 2014 costs of hospitalization and visits to other
treatment units were even less than in African countries –1.67–16.57 US$, standard outpatient
visit was 7.5 US$. Hospital-based services costs for SSm+ patients diagnosed with LPA-based
algorithm were 10.90 US$ per day, which was higher than the corresponding cost for BacTA-
lert of 10.09 US$ and LJ-based algorithm (10.08 US$); for SSm- patients diagnosed with LPA
combined with Bactec MGIT the cost was 8.64 US$ per day and for those diagnosed with com-
bination of LPA and LJ the cost was 8.41 US$; both comparing favorably with cost per day
associated with the LJ-based algorithm (9.28 US$).
Costs for microscopy and DST is a principal parameter which has great influence on cost of
a diagnostic test. The WHO recommends their prices and budgeting: i.e. annual budget
including costs of equipment, maintenance, consumables, human resource, installation and
running costs. But real cost of a test differs worldwide and depends on infrastructure facilities,
and organization of healthcare system in different countries etc. In our study, we evaluated
costs of LJ, Bactec MGIT, BacTAlert and LPA. Comparison with costs of TB diagnostic tests in
other countries showed that these values in Russia were comparable. In 2010–14 costs of cul-
ture-based diagnostic tests in different countries worldwide varied 12.35–15.45 US$ (culture–
LJ), 10.51–52.60 US$ (culture–MGIT), 22.33–23.98 US$ (DST–LJ), 15–232.00 US$ (culture
DST–MGIT), 33.01–38.82 US$ (DST–MGIT+LPA), 1.36–23.07 US$ (DST–LPA on sputum)
[42, 43, 45–53].
In our study costs for microscopy and DST also varied considerably–from 4.96 US$ (LJ) to
181.48 US$ (BacTAlert); resulting in LJ being the least expensive diagnostic tool, followed by
LPA, while BacTAlert and the combination of LPA and Bactec MGIT were the most expensive
DST methods. Medical supplies (i.e., consumables and reagents) were the major determinant
of costs for LPA and LJ tests, but up to 88 samples could be produced from one kit. While
Cost-minimization analysis of LPA
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depreciation of the equipment was rather low. In comparison, BacTAlert was an expensive
DST because of the high cost of equipment and medical supplies per 1 test. Compared to the
cheaper LPA and LJ, BacTAlert was a less attractive diagnostic alternative.
MDR-TB treatment was extremely expensive due to high costs of medications. Their prices
varied significantly in different countries which causes a huge range of cost-effectiveness esti-
mations for new TB diagnostic tools. For example, in India, the cost of second-line standard
treatment regimen for 24 months was 4,204–7,421 [50], in Uganda– 1000.00–5000.00 [52]
(prices in US$2013), in sub-Saharan Africa monthly MDR-TB regimen cost was 119.37–
179.06 [42], in South Africa MDR-TB treatment per day– 2.71–29.52 [43], in Brazil– 120.63–
691.24 [46] (prices in US$2014). In our study over the whole course of treatment average
expenses for MDR-TB medications per patient to the healthcare system were 7369.5 US$. The
mean costs of all medications per day varied between the cohorts from 10.36 US$ (LJ for SSm-
) to 12.73 US$ (for LPA SSm+). These mean costs estimates included 0.6 US$ for the first line
TB medications (H, R, Z, E) per day. The economic evaluation of LPA using the primary clini-
cal outcome of the difference in time from collection of the first sputum specimen to the start
of MDR-TB treatment presented a considerable challenge. Over the short time horizon, the
cost per LPA-diagnosed patient who started on the more expensive MDR-TB drugs earlier
would largely exceed the cost per patient who still continued receiving first line TB treatment
while awaiting the correct diagnosis with an alternative diagnostic method. The immediate
increase in cost of MDR-TB medications was offset by reduction in hospital costs for an aver-
age SSm+ patient. There was no equivalent cost reduction in SSm- patients who received
ambulatory treatment before and after MDR-TB diagnosis. The reduction in cost in SSm-
patients was due to discharging from the hospital. Therefore, LPA-based algorithm provided
cost minimization of health service-related costs for both SSm+ and SSm- patients.
Patient and their guardians (accompanying persons) incured some expenses due to the
additional expenses associated with hospitalization, supplementary medicine and food. LPA-
based diagnosis algorithm corresponded to the speedier assignment of the correct treatment
(by mean value of 50.1 days in comparison to SSm+ patients diagnosed with BacTAlert, and
by 132.3 days in comparison to SSm- patients diagnosed with LJ). The speedier diagnosis
resulted in the earlier discharge of SSm+ patients from hospital, who then faced higher daily
travel expenditures to collect drugs from a medical facility. In our study, most of TB patients
belonged to the socially disadvantaged groups and were entitled to the partially or fully subsi-
dized services such as public transport (travelling to medical facilities for free) or supplemen-
tary medications (provided at a large discount). Our results reflected these social arrangements
showing a daily average out-of-pocket expenses of 0.71 and 0.78 US$ for SSm+ and SSm-
patients respectively, which was equivalent to and showed that patient costs were considerably
smaller than in other countries without similar safety net.
Molecular genetic methods for TB diagnostics proved cost minimization in different
research [37, 45]. Though there is insufficient data of evaluation of cost minimization associ-
ated with implementation of LPA-based algorithm. In our study LPA-based algorithm showed
large cost minimization for the Russian Healthcare system ranging from 780.26 to 2785.60
US$.
Our study had several limitations. The before and after design was associated with an inher-
ent risk of misattributing the cost reduction to the change in diagnostic practices and over-
looking the accumulated effects of other changes in provision of TB treatment. There was only
a limited number of characteristics between the intervention and the control group of patients
that was tested for the statistical significance, so the systematic causes of heterogeneity could
not be ruled out. The prices for medications varied strongly during the study period because
they were imported by different pharmaceutical companies. Medical products bought and
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received by ACAD in many lots and their prices differed considerably. It was impossible to
identify what lot of medications was used for curing the group of MDR-TB patients. To solve
this issue limited prices recommended by Federal Service on Surveillance in healthcare (Rosz-
dravnadzor) [54] were implemented for calculations. It provided neutralizion of inflation fac-
tors but moved to possible inaccuracy of assessment of actual cost of MDR-TB drugs. Since no
data on the actual patient costs in the control group were available, the reduction was attrib-
uted to that possibility that patients faced additional transport costs after earlier discharge
from the hospital under LPA and, therefore the results should be interpreted with caution. In
our study costs associated with LPA and cultural DST were calculated as if every patient was
confirmed with MDR after initial test and there were no erroneous or indeterminate results.
Concordance of LPA and cultural DST was high as published in multiple studies including a
study performed earlier in Arkhangelsk region. At the same time, it was possible that errors
could occur while performing different tests for drug resistance resulting not only in wrong
diagnosis and treatment but also in increased health care costs thus laboratory quality control
was an important issue that should be evaluated.
The study conclusions may be equally valid in other regions of the Russian Federation,
because of the standard MDR-TB treatment practices set by the Federal regulations. Although
the prices of MDR-TB medication and labor costs can differ considerably in various parts of
Russia, our results were robust to variations in costs of medications and costs per bed day.
Genetic molecular methods were recommended by the Ministry of Healthcare but regional
health providers are still using different diagnostic tools to test TB and MDR-TB (solid and liq-
uid mediums in parallel with GeneXpert, country molecular genetic tests: Biochip 2, Synthol,
etc.). Patient costs (as well as household costs) may differ in other regions because of specific
socioeconomic conditions, geographical position of the territory and regional variations in
public health support for TB patients. Arkhangelsk regional TB service is involved in effective
international cooperation due to medical research activity and clinical trials, which help to
realize social initiatives: i.e., free additional food for TB patients, modern equipment for TB
diagnostics, new medications etc.
The benefits of LPA implementation received in our study (reduced time to correct diagno-
sis and treatment initiation and cost minimization) can have positive effects on the dynamics
of the testing/treatment strategy in the other regions of the Russian Federation.
Conclusions
Implementation of the LPA in Arkhangelsk region of the Russian Federation was associated
with both reduction of time to correct MDR-TB diagnosis and cost minimization to the health
care system. Patients diagnosed with LPA also avoided some costs incurred by patients diag-
nosed by conventional methods. The most significant reduction of time to diagnosis and treat-
ment initiation of MDR-TB and the associated cost minimization were observed in the
subgroup of sputum positive patients.
Clinically superior LPA-based algorithm was associated with cost reduction to Russian
healthcare system, and total cost minimization in treatment-related expenditures to patients
most of whom belong to the low-income subgroup. Our comparative economic analysis of
MDR-TB diagnostics and treatment algorithms suggested that a targeted subsidy/home treat-
ment might provide an incentive for MDR-TB patients to stay in treatment and lessen the bur-
den of disease.
The LPA-based diagnostic and treatment algorithms were more effective in delivering the
correct diagnosis sooner and are also less expensive than the alternatives. Therefore, the LPA
was a dominant intervention.
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